Azitra, Inc., a clinical-stage biopharmaceutical company based in Branford, Connecticut, is set to present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City. The company’s Cofounder and Chief Operating Officer, Travis Whitfill, PhD, MPH, will deliver a virtual presentation on September 8 at 07:00 AM ET, focusing on significant advancements in Azitra’s clinical pipeline.
In his presentation, Dr. Whitfill will discuss the promising safety results emerging from the Phase 1b clinical trial of the ATR-12 program, aimed at treating Netherton syndrome. This rare genetic condition currently has no approved treatments and can lead to severe complications, particularly in infants. Furthermore, he will share details about the successful dosing of the first patient in the Phase 1/2 clinical trial of the ATR-04 program, which addresses dermal toxicity associated with EGFR inhibitors in adults.
Key Developments in Azitra’s Pipeline
The ATR-12 program utilizes an engineered strain of Staphylococcus epidermidis designed specifically to combat the debilitating effects of Netherton syndrome. Azitra’s clinical trials are critical as they aim to provide effective therapies for patients who currently face significant health challenges without viable treatment options.
Additionally, the ATR-04 program focuses on treating rashes caused by EGFR inhibitors, a class of drugs commonly used in cancer therapies. This condition affects approximately 150,000 people in the United States alone. The company has received Fast Track designation from the FDA for this program, highlighting its potential significance in the healthcare landscape.
Engagement Opportunities at the Conference
During the conference, Dr. Whitfill will engage in one-on-one meetings with registered investors and potential partners. This interaction aims to showcase Azitra’s comprehensive business strategy and recent corporate achievements, while also outlining anticipated milestones for its clinical programs.
Azitra’s innovative approach combines a proprietary platform of engineered proteins and topical live biotherapeutic products, which is further enhanced by artificial intelligence and machine learning technologies. This unique combination allows the company to analyze and predict optimal bacterial strains for drug development effectively.
For those interested in viewing the presentation, a webcast link is available: Webcast Link.
As the biopharmaceutical sector continues to evolve, Azitra, Inc. remains at the forefront of developing precision dermatology therapies. The upcoming conference represents a pivotal moment for the company to share its vision and progress with a broader audience.
For additional information about the company and its initiatives, visit azitrainc.com.
Forward-looking statements in this announcement reflect current expectations and are subject to various risks and uncertainties. It is crucial for stakeholders to consider these factors as Azitra moves forward with its clinical programs.